Corindus Vascular Robotics (CVRS) 8-K Regulation FD Disclosure

Precision Vascular Robotics

Corindus Vascular Robotics (CVRS)

Overview

August 2015

Exhibit 99.1

FORWARD

LOOKING

STATEMENTS

THIS

PRESENTATION

CONTAINS

“FORWARD-LOOKING

STATEMENTS”

(AS

SUCH

TERM

IS

DEFINED

IN

SECTION

27A

OF

THE

SECURITIES

ACT

OF

1933,

AS

AMENDED,

AND

SECTION

21E

OF

THE

SECURITIES

EXCHANGE

ACT

OF

1934,

AS

AMENDED,

AND

INFORMATION

RELATING

TO

THE

COMPANY,

THAT

ARE

BASED

ON

THE

CURRENT

BELIEFS

OF,

AND

ASSUMPTIONS

MADE

BY

OUR

MANAGEMENT

AND

THE

INFORMATION

CURRENTLY

AVAILABLE

TO

OUR

MANAGEMENT.

FORWARD-LOOKING

STATEMENTS

RELATE

TO

EXPECTATIONS

CONCERNING

MATTERS

THAT

ARE

NOT

HISTORICAL

FACTS.

WORDS

SUCH

AS

"ANTICIPATE,"

"BELIEVE,"

"ESTIMATE,"

"EXPECT,"

"INTEND,"

"PLAN,"

"PREDICT,"

"OPINION,"

"WILL"

AND

SIMILAR

EXPRESSIONS

AND

THEIR

VARIANTS,

ARE

INTENDED

TO

IDENTIFY

FORWARD-LOOKING

STATEMENTS.

THESE

FORWARD-LOOKING

STATEMENTS

INCLUDE,

BUT

ARE

NOT

LIMITED

TO

STATEMENTS

RELATED

TO

OUR

EXPECTED

BUSINESS,

PRODUCTS,

ADOPTION

OF

ROBOTIC

MEDICAL

PROCEDURES,

RESULTS

OF

OPERATIONS,

FUTURE

FINANCIAL

CONDITION,

ABILITY

TO

INCREASE

OUR

REVENUES,

FINANCING

PLANS

AND

CAPITAL

REQUIREMENTS,

OR

COSTS

OF

REVENUE,

EXPENSES,

POTENTIAL

TAX

ASSETS

OR

LIABILITIES,

EFFECT

OF

RECENT

ACCOUNTING

PRONOUNCEMENTS,

CASH

FLOWS

AND

ABILITY

TO

FINANCE

OPERATIONS

FROM

CASH

FLOWS,

AND

SIMILAR

MATTERS.

THESE

FORWARD-LOOKING

STATEMENTS

SHOULD

BE

CONSIDERED

IN

LIGHT

OF

VARIOUS

IMPORTANT

FACTORS,

INCLUDING,

WITHOUT

LIMITATION,

THE

IMPACT

OF

GLOBAL

AND

REGIONAL

ECONOMIC

AND

CREDIT

MARKET

CONDITIONS

ON

HEALTH

CARE

SPENDING;

HEALTH

CARE

REFORM

LEGISLATION

IN

THE

UNITED

STATES

AND

ITS

IMPACT

ON

HOSPITAL

SPENDING,

REIMBURSEMENT

AND

FEES

WHICH

WILL

BE

LEVIED

ON

CERTAIN

MEDICAL

DEVICE

REVENUES,

DECREASES

IN

HOSPITAL

ADMISSIONS

AND

ACTIONS

BY

PAYERS

TO

LIMIT

OR

MANAGE

SURGICAL

PROCEDURES

TIMING

AND

SUCCESS

OF

PRODUCT

DEVELOPMENT

AND

MARKET

ACCEPTANCE

OF

DEVELOPED

PRODUCTS,

PROCEDURE

COUNTS;

REGULATORY

APPROVALS,

CLEARANCES

AND

RESTRICTIONS;

GUIDELINES

AND

RECOMMENDATIONS

IN

THE

HEALTH

CARE

AND

PATIENT

COMMUNITIES,

INTELLECTUAL

PROPERTY

POSITIONS

AND

LITIGATION,

COMPETITION

IN

THE

MEDICAL

DEVICE

INDUSTRY

AND

IN

THE

SPECIFIC

MARKETS

OF

SURGERY

IN

WHICH

WE

OPERATE,

THE

INABILITY

TO

MEET

DEMAND

FOR

PRODUCTS,

THE

RESULTS

OF

LEGAL

PROCEEDINGS

TO

WHICH

WE

ARE

OR

MAY

BECOME

A

PARTY,

PRODUCT

LIABILITY

AND

OTHER

LITIGATION

CLAIMS,

ADVERSE

PUBLICITY

REGARDING

OUR

COMPANY

AND

SAFETY

OF

OUR

PRODUCTS

AND

THE

ADEQUACY

OF

TRAINING;

OUR

ABILITY

TO

EXPAND

IN

FOREIGN

MARKETS;

AND

OTHER

RISK

FACTORS.

READERS

ARE

CAUTIONED

NOT

TO

PLACE

UNDUE

RELIANCE

ON

THESE

FORWARD-LOOKING

STATEMENTS,

WHICH

ARE

BASED

ON

CURRENT

EXPECTATION

AND

ARE

SUBJECT

TO

RISKS,

UNCERTAINTIES;

AND

ASSUMPTIONS

THAT

ARE

DIFFICULT

TO

PREDICT,

INCLUDING

THOSE

RISK

FACTORS

DESCRIBED

IN

THE

COMPANY’S

PROSPECTUS

FILED

IN

CONJUNCTION

WITH

AN

S-1

REGISTRATION

STATEMENT

ON

MAY

26,

2015.

OUR

ACTUAL

RESULTS

MAY

DIFFER

MATERIALLY

AND

ADVERSELY

FROM

THOSE

EXPRESSED

IN

ANY

FORWARD-LOOKING

STATEMENTS.

WE

UNDERTAKE

NO

OBLIGATION

TO

PUBLICLY

UPDATE

OR

RELEASE

ANY

REVISIONS

TO

THESE

FORWARD-LOOKING

STATEMENTS

EXCEPT

AS

REQUIRED

BY

LAW.

NOT

AN

OFFER

THIS

PRESENTATION

IS

FOR

INFORMATIONAL

PURPOSES

ONLY.

THE

MATERIALS

DO

NOT

CONSTITUTE

EITHER

AN

OFFER

TO

SELL

SECURITIES

OR

THE

SOLICITATION

OF

AN

OFFER

TO

BUY

SECURITIES.

2

•

CorPath

®

System: Only FDA cleared

robotic-assisted percutaneous coronary

intervention (“PCI”) system

•

PCI is a high volume, (~933k), US medical

robotics procedure opportunity; long

growth runway

•

Cath Lab occupational hazards concerns

and awareness are growing

•

CorPath installed base for commercial

foundation and regional show sites

•

Expanding sales team and building funnel

across US

3

Corindus Growth Platform

Interventional robotics leadership

Protection

Staff  Safety

Precision

Clinical Outcomes

Promotion

Hospital Growth

New

Standard

of Care

New

Standard

of Care

Experienced Leadership Team

Experience in the cardiovascular field

4

David Handler

President

& CEO

David Long

VP Finance, CFO

Management

Strong Investor Base

Cath

Lab Procedure Innovation

CorPath Robotic-assisted PCI

1986

First Stent

Procedure

2013

Procedure

Unchanged

>>

5

PCI procedure remains largely unchanged since introduction

•

Innovation historically focused on stents and delivery systems

•

Traditional PCI not optimized to required levels of complexity, dexterity and

precision

The CorPath System offers:

•

Physicians/Staff

–

radiation

and

orthopedic

safety

and

robotic

precision

•

Patients

–

potential to improve clinical outcomes

•

Hospitals

-

differentiation

2015

CorPath Robotic

PCI

Vascular Robotics Market

CorPath platform potential to expand vascular indications

Corindus IP and Technology

6

Coronary

Peripheral

Neuro

Structural

Corindus Market Opportunity

$4.5B

FY2018

market

estimate

7

•

New System Sales annual market opportunity based on 5-year replacement cycle in 5,430 US labs and 8,150 OUS labs,

at a blended average price per system of $350,000. Prices vary by procedure type and geography.

•

Non-PCI

procedure

types

are

Peripheral

Vascular

1

,

Neurointerventional

and

Structural

Heart.

•

Consumables annual sales based on year 2018 estimated PCI annual procedure volume of 933,000 in the US and

1,800,000 OUS, and  non-PCI annual procedure volumes of 1,200,000 in the US and 1,800,000 OUS, at an average

selling

price

of

$550

per

CorPath

cassette.

2

•

The

annual

service

revenue

opportunity

of

$474mm

is

based

on

blended

average

price

of

$35,000

per

annual

service

contract.

•

Model does not account for custom Corindus catheter devices, or OUS opportunities beyond Europe, Japan and China,

which could significantly expand market opportunity.

1

Peripheral Vascular includes lower limb, carotid, renal, iliac and AAA  (abdominal aortic aneurysm) procedures

2

Market opportunity assessment based on market research reports and Corindus estimate

New Systems

($, mm)

Consumables

($, mm)

Service

($, mm)

Total Revenue

Opportunity

($, mm)

US

$244

$513

$122

$879

-PCI

$218

$862

$109

$1,190

subtotal

$462

$1,375

$231

$2,068

OUS

$256

$757

$128

$1,141

-PCI

$229

$1,006

$115

$1,350

subtotal

$485

$1,763

$243

$2,491

Worldwide opportunity

$947

$3,138

$474

$4,559

2

Product Overview

8

CorPath Robotic-Assisted PCI System

9

CorPath Robotic-Assisted PCI System

10

CorPath Installation

•

The CorPath system fits in any cath lab and is

compatible with all fluoroscopy systems; Philips,

GE, Siemens, Toshiba.

•

No construction is required. Several electronic

cables are used to connect the bedside with the

cockpit for robotics and imaging. Typical

installation is one day.

•

The CorPath cockpit is on wheels and can be

moved within the room.

Customer Training

•

Initial site training is completed in approximately

four hours.

•

Training includes both physicians and cath lab

staff.

•

Often the first commercial case is performed

within a few days of initial installation.

Today’s Cath Lab Challenges

Staff Safety and Health is at Risk

•

The cath lab is a dangerous environment for workers

»

Radiation exposure

cancer and cataract risk

»

Ergonomic Strain

orthopedic injury and chronic

pain

Procedure Outcomes Not Optimal

•

Difficulty viewing angiography standing at bedside

•

Inconsistent visual assessment of length and location

•

Variations in manual skill limits deployment accuracy

Hospital Economics Are Inefficient

•

Above factors lead to:

»

Increased stent usage

»

Costly complications

»

Restenosis/revascularization

•

Highly competitive market for PCI procedures

•

Increasing CMS outpatient PCI reimbursement rates in

2015

Foreshortened coronary angiogram

Traditional angioplasty

11

•

Lab ergonomics create awkward working

positions

•

Lead protection exacerbates stress loading –

pressures up to 300 psi on discs propagating

“interventionalist disc disease”

•

High radiation exposure –

increased risk of

brain tumor, leukemia/lymphoma, cataracts

Safety in a Hazardous Environment

Reduce radiation exposure, orthopedic injury and pain

•

Radiation shielded work station reduces

exposure from head to toe

•

Improved

ergonomics

-

work

from

a

seated

position

•

No

need

to

wear

lead

while

in

cockpit

-

reduced

stress and fatigue

•

Corindus-sponsored PRECISE study

demonstrated 95.2% median reduction in

physician radiation exposure

12

Traditional PCI

CorPath

Robotic PCI

Escalating Awareness of Risks

Accelerating publication frequency

ORSIF, February 2015

JACC Interventions, April 2015

JACC, March 2015

CCI, April 2015

CCI, February 2015

13

Occupational Risks in the Cath

Lab

•

Brain tumors

–

Reported brain tumors are

predominately left-side amongst

interventionalists

•

Orthopedic injuries

2,4

–

60% incidence of spine issues after 21

years in practice

–

42% incidence of spine problems -

General

population

average

rate

-

2.3%

–

33% miss work due to orthopedic issues

•

Cataracts

–

50% have significant posterior

subcapsular

lens

changes.

14

Radiation and orthopedic injury

1

Roguin

A.

Radiation

hazards

to

interventional

cardiologists:

A

report

on

increased

brain

tumors

among

physicians

working

in

the

cath

lab.

SOLACI

2014;

April

23,

2014;

Buenos

Aires,

Argentina.

2

Gregory

Dehmer

et

al.,

Occupational

Hazards

for

Interventional

Cardiologists,

The

Society

for

Cardiovascular

Angiography

and

Interventions,

68

Catheterization

andCardiovascular

Interventions

974,

975 (2006),

http://www.scai.org/asset.axd?id=c01541b7-66c2-46a4-940e-e2a55e71e5bc&t=633945866505100000

3

E. Vano, et al.

Radiation-associated

lens

opacities

in

catheterization

personnel:

results

of

a

survey

and

direct

assessments.

24

Journal

of

Vascular

Interventional

Radiology

2:

197-204 (2013).

4

Goldstein

JA,

Balter

S,

Cowley

M

et

al.

Occupational

hazards

of

interventional

cardiologists:

prevalence

of

orthopedic

health

problems

in

contemporary

practice.

Catheter

Cardiovasc

Interv

2004;

63:407-211.

15558765

1

3

Enhanced procedure may improve outcomes, economics and safety

Traditional PCI vs. CorPath

®

Robotic PCI

15

Struggle to see

angiography

Close

proximity

ergonomic

visualization

Trial & error, wire

spinning

Precise ‘Point & Shoot’

predictability

‘Eyeball’ estimate

Robotic-assisted

sub-mm

Measurement

Manual adjustment

1mm precise

positioning

Devices loose during

inflation

Fixated devices during

deployment

Open Architecture System

•

Compatible with off-the-

shelf guide wires, balloons

and stents from Medtronic,

Abbott, BSC etc.

Traditional

PCI

CorPath

Robotic PCI

PCI

steps

Assess

Anatomy

Navigate

Measure

Anatomy

Position

Stent

Deploy

Stent

•

Inaccurate lesion assessment

–

~65% physicians select stent length based on visual

estimation alone

1

–

51% of physicians underestimated lesion length

2

–

Inaccurate estimate lead to sub-optimal PCI procedure

and can cause LGM

•

Longitudinal Geographic Miss (LGM) correlates with

higher TVR

–

STLLR trial demonstrated high incidence of LGM

3

•

Published Journal American College of Cardiology;

•

1,557 patients, 41 US hospitals; 1 year follow up

–

47.6%* of patients had LGM stent placements

–

LGM leads to 2.3x incidence of TVR

16

1

65% according to an online survey, Junicon

market research 2012 –

113 interventional cardiologists. Study sponsored by Corindus Inc.

2

Campbell, P. T et al (2015), Interoperator

and intraoperator

(in)accuracy of stent selection based on visual estimation. Catheterization and Cardiovascular 

Intervention.

doi:

10.1002/ccd.2578 , Study sponsored by Corindus Inc.

3

Costa M., et al. Impact of Stent Deployment Procedural Factors on Long-Term Effectiveness and Safety of Sirolimus-Eluting Stents. Am J Cardiol, 101(12):1704-11  2008

*Analyzable data set included 1419 patients (required LGM and AGM data)

Precision Matters in PCI

How does precision impact patients?

Longitudinal Geographic Miss (LGM)

Target Vessel Revascularization (“TVR”) =

Repeat PCI or worse!

(increased

patient risk and cost implications)

1

Nikolsky

E,

Pucelikova

T,

Mehran

R,

et

al.

An

Evaluation

of

fluoroscopy

time

and

correlation

with

outcomes

after

percutaneous

coronary

intervention.

J

Invasive

Cardiol,

2007,

19:

208-213

2

Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention. J American College of Cardiol, 2013,  Vol 61, No. 15: 1596-1600

3

Core lab assessment of Longitudinal Geographic Miss on PRECISE dataset, data on file, Corindus Inc.

•

PRECISE

2

study showed compared to Nikolsky

1

:

9% fewer stents

16% reduction in fluoro time

40% less contrast used

•

PRECISE study showed 12% LGM vs. 48% in STLLR

3

Nikolsky et al, 2007

[1]

Fluoro time

23 min

(N=7,242 pts)

PRECISE study

[2]

(N=164 pts)

Age

63.9 ±11.8

64.1±10.0

Lesion

length

(mm)

12.8 ±

6.7

13.4±

4.0

Number

of

Stents

1.20 ±

0.83

1.1 ±

0.34

Fluoroscopy

time

(min)

12.7 ±

5.1

10.6 ±

6.2

Contrast Volume (ml)

242 ±

100

144.2 ±70

PRECISE vs. Historical Data

Compares CorPath robotic vs. historical PCI procedure

17

18

Clinical Evidence –

Precision Matters

Peer reviewed publication highlights

Continued Investment in Clinical Data

•

Post PRECISE sub-analysis

•

PRECISION registry post market data

collection and analysis vs. manual

procedures

•

Concurrent studies to prove procedure

benefits of CorPath robotic precision vs.

manual procedures

»

Reduced LGM

»

Measurement accuracy

»

Visualization

»

Stent utilization

»

Contrast utilization

»

Radiation exposure

Commercial Strategy

19

Sales Strategy

Dedicated system and cassette sales teams

System Sales Team

•

Experienced

medical

technology

sales

professionals

–

System

‘hunters’

•

Sales process initiates with Interventional Cardiologist champion, then progresses

through hospital administration

•

Leveraging both capital purchase and utilization models to accelerate sales

•

Increasing field team to 12 people in 2015

•

Focused on largest market areas

Clinical Sales Team

•

Experienced

interventional

procedure/device

sales

–

procedure

‘builders’

•

Initial site training and program launch

•

Drive  procedures and cassette sales, in depth account focus. Cath lab presence.

•

Continuous use and adoption by new physician and staff users

Two sales teams working together to provide experienced

interventional cardiology leadership.

20

21

Intellectual Property

Intellectual Property Overview

Expanding on a strong foundation

Continuous “Ring-fencing” all vascular robotics

applications:

•

38 issued global patents

•

51 patents pending: broad application coverage

•

Continuously building IP portfolio

•

Pursuing the vascular space broadly

Corindus

IP

covers

remote

control

of

two

or

more

co-axial

devices

-

a

requirement for PCI and many vascular procedures

22

23

Financials

Key Financial Information

Key Metrics*

Cash, Cash Equivalents and Marketable Securities

$58.9 million

Debt**

$10.0 million

Basic Shares Outstanding

118,533,157

Warrants Outstanding

5,207,379

Stock Options Outstanding

8,597,961

* As of June 30, 2015

** Outstanding principal balance

24

25

Summary

•

Cath Lab occupational hazards concerns and

awareness are growing

•

PCI is a very large volume medical robotics

procedure opportunity; long growth runway

•

Growing CorPath installed base for

commercial foundation and regional show

sites

•

Sales team expansion and funnel building

across US

•

Building technology and clinical experience

for next application growth markets:

Peripheral, Neuro, Structural Heart

26

Corindus Growth Platform

Interventional robotics leadership

Precision Vascular Robotics

The New Standard of Care in Vascular Procedures

27

About Corindus Vascular Robotics

Corindus Vascular Robotics is a global technology

leader in robotic-assisted percutaneous coronary

interventions. The company’s CorPath System is

the first medical device that offers interventional

cardiologists PCI procedure control from an

interventional cockpit.

Visit us at www.corindus.com